2026 Payer IT Outsourcing Outlook: Outcome-Based Managed Services, Production-Grade GenAI Governance, and Vendor-Risk Enforcement 
RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
- Initiated prestIgE Phase 2b trial of ozureprubart in food allergy - Announced positive topline data from Phase 2 trial...
Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program
All 84 clinical sites across the U.S. are fully activated, enrolling, and treating patients The first group of participants reached...
LB Pharmaceuticals Reports 3Q 2025 Financial Results and Recent Corporate Updates
NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced...
Celldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study
HAMPTON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data on exploratory endpoints (UCT7) further demonstrating barzolvolimab’s...
Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors
Exclusive collaboration and license agreement focuses on advancing novel T cell therapy “Seed-and-Boost” approach exploiting the mechanism of the CUE-100...
Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patients with ColdU and 49% with SD Obtain Complete Response at Week 20
First large, randomized, placebo-controlled study to demonstrate clinical benefit in patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD)All primary...
Sironax Announces Three Abstracts Selected for Presentation at Neuroscience 2025
Society for Neuroscience Annual Meeting, November 15-19, San Diego, CAWALTHAM, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sironax, a global...
CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy
SINGAPORE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical...
Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results
Quarterly Revenue Growth of 13% to ~$68 Million Gross Margin Increased to 43% on Improved Execution and Operational Efficiency Best-in-Class...
VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update
Company is progressing its previously initiated strategic review evaluating a range of options to maximize shareholder value, including assessment of...
Nucleome Therapeutics founder Professor James Davies and Oxford University publish paper in prestigious journal Cell
Groundbreaking research using Nucleome MCC technology reveals complex structure of DNA inside living cells at base pair resolution for the...
Abzena and Mabqi Announce Strategic Partnership to Offer Integrated Discovery through Development Solution
SAN DIEGO and MONTPELLIER, France, Nov. 6, 2025 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates,...
Millennium Technology Prize opens its nomination period for innovations for a better life
HELSINKI, Nov. 6, 2025 /PRNewswire/ -- The world's leading innovation award, Millennium Technology Prize, will be awarded again in May...
SlicedHealth Elevates Hospital Contract Intelligence with SlicedIQ
New HIPPA-Compliant AI technology for Contract Modeling and Variance Analysis to Revolutionize Hospital Revenue Cycle Optimization WOODSTOCK, GA / ACCESS...
Defence Announces Successful Presentation at the World ADC Conference in San Diego and Plans to Expand Evaluation of Accum in Commercial and Pipeline ADCs
Montreal, Quebec--(Newsfile Corp. - November 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the...
TIME Recognizes Arya Health as a Top HealthTech Company of 2025
Exclusive Recognition Highlights Arya Health as the First Choice in Canadian Electronic Medical Records Software VANCOUVER, BC, Nov. 5, 2025...
The Michael J. Fox Foundation for Parkinson’s Research Applauds Texas Voters on Passage of Proposition 14 Securing $3 Billion for Brain Disease Research
The ballot measure was supported by national and local neurodegenerative disease organizations, including The Michael J. Fox Foundation (MJFF). MJFF...
Medtronic to announce financial results for its second quarter of fiscal year 2026
GALWAY, Ireland, Nov. 5, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it...
Illumina Responds to Positive Updates from Chinese Ministry of Commerce
SAN DIEGO, Nov. 5, 2025 /PRNewswire/ -- The Chinese Ministry of Commerce (MOFCOM) today announced it will lift the export ban...
Columbus McKinnon to Present at the 2025 Baird Global Industrial Conference
CHARLOTTE, N.C., Nov. 5, 2025 /PRNewswire/ -- Columbus McKinnon Corporation (Nasdaq: CMCO) ("Columbus McKinnon" or the "Company"), today announced that it...